Please click the links below to download pdf
2012 - A First-in-Human, Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-Based PSMA-Activated Prodrug,
            in Patients with Advanced Solid Tumors
2012 - Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy
2009 - Amino Acid Containing Thapsigargin Analogs Deplete Androgen Receptor Protein Via Synthesis Inhibition and Induce the Death of Prostate Cancer Cells
2009 - A Trojan Horse in Drug Development: Targeting of Thapsigargins Toward Prostate Cancer Cells
2006 - Pharmacokinetics, Biodistribution, and Antitumor Efficacy of a Human Glandular Kallikrein 2 (hK2)-Activated Thapsigargin Prodrug
2003 - Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer
2001 - Design, Synthesis, and Pharmacological Evaluation of Thapsigargin Analogues for Targeting Apoptosis to Prostatic Cancer Cells